# Data Sheet

| | |
|---|---|
| **Product Name:** | JNJ-38877618 |
| **Cat. No.:** | CS-0034063 |
| **CAS No.:** | 943540-74-7 |
| **Molecular Formula:** | $C_{20}H_{12}F_2N_6$ |
| **Molecular Weight:** | 374.35 |
| **Target:** | c-Met/HGFR |
| **Pathway:** | Protein Tyrosine Kinase/RTK |
| **Solubility:** | DMSO : 5 mg/mL (13.36 mM; Need ultrasonic) |



## BIOLOGICAL ACTIVITY:

JNJ-38877618 is a potent, highly selective, orally bioavailable **Met** kinase inhibitor with **$IC_{50}$**s of 2 and 3 nM for wild type and mutant Met, respectively. IC50 & Target: IC50: 2 nM (wt Met), 2 nM (mutant Met)[1] ***In Vitro:*** OMO-1 (formerly JNJ-38877618), is a potent, highly selective, orally bioavailable Met kinase inhibitor with nM binding affinity ($K_d$=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant Met (2 and 3 nM $IC_{50}$). Met inhibitory effects are assessed in proliferation, colony formation and motility assays. JNJ-38877618 displays nM potency against Met Ampl/mutant and therapy resistant models[1]. ***In Vivo:*** JNJ-38877618 induces complete inhibition of tumor growth in 3 models: the SNU5 Met amp gastric, U87-MG HGF autocrine glioblastoma and Hs746T Met exon 14 skipping mutant gastric cancer. JNJ-38877618 induces regression of large Met amplified EBC-1 SqNSCLC where JNJ-38877618 leads to dose- and time-dependent inhibition of Met kinase activation, with the duration of target shut down considerably exceeding plasma exposure times. Combination treatments are well tolerated and improved EGFR targeted therapy[1].

## References:

[1]. Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4791.

## CAIndexNames:

Quinoline, 6-[difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]-

## SMILES:

FC(C1=CC=C2N=CC=CC2=C1)(F)C3=NN=C4C=CC(C5=CC=NC=C5)=NN43

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA